Balchem Corporation (NASDAQ: BCPC) today reported for the second
quarter 2019 net earnings of $19.8 million, compared to net
earnings of $19.7 million for the second quarter 2018. Second
quarter adjusted net earnings(a) were $25.2 million, compared to
$24.5 million in the prior year quarter. Second quarter
adjusted EBITDA(a) was $40.0 million, compared to $40.5 million in
the prior year quarter.
Second Quarter 2019 Financial Highlights:
- Second quarter net sales of $161.6 million, a decrease of $2.1
million, or 1.3%, compared to the prior year quarter.
- Year over year quarterly sales growth in three of the four
segments, with record second quarter sales in Human Nutrition and
Health and Animal Nutrition and Health.
- Second quarter GAAP net earnings were $19.8 million, an
increase of $0.2 million, or 0.8% from the prior year, primarily
due to a favorable mix, lower interest expense, and lower tax
expense. These net earnings resulted in GAAP earnings per share of
$0.61. Quarterly adjusted net earnings of $25.2 million increased
$0.7 million or 2.9% from the prior year, resulting in adjusted
earnings per share(a) of $0.77.
- Second quarter adjusted EBITDA was $40.0 million, a decrease of
$0.6 million, or 1.4%, from the prior year.
- Quarterly cash flows from operations were $26.3 million for the
second quarter 2019, an increase of 24.1% from the prior year, with
quarterly free cash flow(a) of $20.1 million, an increase of 16.7%
from the prior year.
Recent Highlights:
- On May 27, 2019, the acquisition of Chemogas was
completed. Chemogas, headquartered in Grimbergen, Belgium, is
a leader in the packaging and distribution of a wide variety of
specialty gases, most notably ethylene oxide for medical device
sterilization, primarily in the European and Asian markets.
With this acquisition, Balchem significantly expands its geographic
presence in the packaged ethylene oxide market, enabling the
company to offer worldwide service and support to its medical
device sterilization customers. The Chemogas sites in Europe and
Asia will form a global network of facilities when combined with
Balchem’s sites in the United States, making Balchem the global
leader in the critical supply of ethylene oxide to the medical
device sterilization industry.
- Cornell University has conducted a follow-on study related to
its choline supplementation during pregnancy study, to see if the
cognitive benefits seen in the first year of life during the
initial study, persist into later childhood. The researchers
at Cornell have conducted extensive neurologic and cognitive
testing on the same children who are now seven years old.
Preliminary results have been presented at several international
scientific meetings and show that increasing maternal choline does
indeed improve attention, memory, and executive function at seven
years of age.
Ted Harris, Chairman, CEO, and President of
Balchem said, “We are pleased with the progress made in the second
quarter, along with the growth in Human Nutrition and Health and
Animal Nutrition and Health, and we are excited about the
completion of the Chemogas acquisition. We are also very encouraged
by the progress made around the research supporting our choline
franchise and its role as an essential nutrient for both humans and
animals, and we believe this will help strengthen our value
proposition and support our continued growth into the future.”
Results for Period Ended June 30,
2019 (unaudited)(Dollars in thousands, except per share
data)
|
|
Three Months Ended June 30, |
|
Six Months EndedJune 30, |
|
|
2019 |
|
2018 |
|
2019 |
|
2018 |
Net sales |
|
$ |
161,554 |
|
|
$ |
163,687 |
|
|
$ |
318,583 |
|
|
$ |
325,097 |
|
Gross margin |
|
53,918 |
|
|
53,466 |
|
|
103,013 |
|
|
104,925 |
|
Operating expenses |
|
27,516 |
|
|
26,363 |
|
|
50,131 |
|
|
50,582 |
|
Earnings from operations |
|
26,402 |
|
|
27,103 |
|
|
52,882 |
|
|
54,343 |
|
Other expense |
|
1,521 |
|
|
2,042 |
|
|
3,208 |
|
|
4,105 |
|
Earnings before income tax
expense |
|
24,881 |
|
|
25,061 |
|
|
49,674 |
|
|
50,238 |
|
Income tax expense |
|
5,052 |
|
|
5,382 |
|
|
11,062 |
|
|
11,213 |
|
Net earnings |
|
$ |
19,829 |
|
|
$ |
19,679 |
|
|
$ |
38,612 |
|
|
$ |
39,025 |
|
|
|
|
|
|
|
|
|
|
|
Diluted net earnings per
common share |
|
$ |
0.61 |
|
|
$ |
0.61 |
|
|
$ |
1.19 |
|
|
$ |
1.21 |
|
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA(a) |
|
$ |
39,979 |
|
|
$ |
40,530 |
|
|
$ |
79,659 |
|
|
$ |
81,270 |
|
Adjusted net earnings(a) |
|
$ |
25,246 |
|
|
$ |
24,530 |
|
|
$ |
48,976 |
|
|
$ |
48,948 |
|
Adjusted net earnings per
common share(a) |
|
$ |
0.77 |
|
|
$ |
0.76 |
|
|
$ |
1.51 |
|
|
$ |
1.51 |
|
|
|
|
|
|
|
|
|
|
|
Shares used in the
calculations of diluted and adjusted net earnings per common
share |
|
32,583 |
|
|
32,438 |
|
|
32,540 |
|
|
32,378 |
|
(a) |
See “Non-GAAP Financial Information” for a reconciliation of GAAP
and non-GAAP financial measures. |
Financial Results for the Second Quarter of
2019:
The Human Nutrition &
Health segment generated second quarter sales of $85.9
million, an increase of $0.9 million or 1.0% compared to the prior
year quarter. The increase was driven by higher sales within our
Human Nutrition & Pharma and Ingredient Solutions businesses,
partially offset by a decrease in Cereal Systems sales. Quarterly
earnings from operations for this segment of $12.3 million
increased $2.7 million or 27.4% compared to $9.7 million in the
prior year quarter, primarily due to the aforementioned higher
sales, mix, and lower operating expenses. Excluding the effect of
non-cash expense associated with amortization of acquired
intangible assets for the second quarter of 2019 and 2018 of $4.9
million and $5.4 million, respectively, adjusted earnings from
operations(a) for this segment were $17.2 million, compared to
$15.1 million in the prior year quarter.
The Animal Nutrition &
Health segment generated quarterly sales of $43.5 million,
an increase of $1.4 million or 3.4% compared to the prior year
quarter. The increase was primarily the result of higher sales of
ruminant animal feed market products. Second quarter earnings from
operations for this segment of $5.0 million were down from the
prior year comparable quarter of $7.0 million, primarily due to
lower feed grade choline volumes and margins in the European
monogastric business as a result of increased competitive activity.
Excluding the effect of non-cash expense associated with
amortization of acquired intangible assets for the second quarter
of 2019 and 2018 of $0.2 million and $0.1 million respectively,
adjusted earnings from operations for this segment were $5.2
million, compared to $7.1 million in the prior year quarter.
The Specialty Products segment
generated second quarter sales of $24.9 million, an increase of
$2.0 million or 8.9% compared to the prior year quarter, primarily
due to higher sales of ethylene oxide for the medical device
sterilization market due to both the contribution of Chemogas and
higher legacy volumes, partially offset by lower volumes in the
plant nutrition business. Second quarter earnings from operations
for this segment were $8.9 million, versus $8.7 million in the
prior year comparable quarter, an increase of $0.2 million or 2.4%,
primarily due to the aforementioned higher sales, partially offset
by higher operating expenses due to the acquisition of
Chemogas. Excluding the effect of non-cash expense associated
with amortization of acquired intangible assets for the second
quarter of 2019 and 2018 of $1.1 million and $0.7 million,
respectively, adjusted earnings from operations for this segment
were $10.0 million, compared to $9.4 million in the prior year
quarter.
The Industrial Products segment
sales of $7.3 million decreased $6.5 million or 47.0% from the
prior year comparable quarter, primarily due to reduced sales
volumes of choline and choline derivatives used in shale fracking
applications. Earnings from operations for the Industrial Products
segment were $0.9 million, a decrease of $1.7 million or 65.1%
compared with the prior year comparable quarter, primarily due to
the aforementioned lower sales volumes.
Consolidated gross margin for the quarter ended
June 30, 2019 of $53.9 million increased by $0.5 million or
0.8%, compared to $53.5 million for the prior year comparable
period. Gross margin as a percentage of sales was 33.4% as compared
to 32.7% in the prior year period. The increase was primarily due
to mix, partially offset by lower feed grade choline volumes and
margins in the European monogastric business. Operating expenses of
$27.5 million for the quarter increased $1.2 million from the prior
year comparable quarter, primarily due to incremental operating
expenses related to the Chemogas acquisition and increased bad debt
expense. Excluding non-cash operating expenses associated with
amortization of intangible assets of $6.1 million, operating
expenses were $21.4 million, or 13.2% of sales.
Interest expense was $1.5 million in the second
quarter of 2019. Our effective tax rates for the three months ended
June 30, 2019 and 2018 were 20.3% and 21.5%, respectively. The
decrease in the effective tax rate from the prior year is primarily
due to discrete items.
For the quarter ended June 30, 2019, cash
flows provided by operating activities were $26.3 million, and
quarterly free cash flow was $20.1 million. The $169.8 million of
net working capital on June 30, 2019 included a cash balance
of $41.7 million, which reflects second quarter 2019 revolving loan
and acquired debt payments of $32.2 million and capital
expenditures of $6.2 million. The Company continues to invest in
projects across all facilities to improve capabilities and
operating efficiencies.
Ted Harris, CEO and President of Balchem said,
“Our second quarter earnings once again highlight the resilience of
our business model, particularly in light of the specific headwinds
we faced in the quarter, predominantly in the Industrial Products
segment with the oil and gas business. Moving forward, we will
continue to drive our strategic growth initiatives, through both
organic investments in new manufacturing capabilities and new
product development, as well as value creating acquisitions.”
Quarterly Conference CallA
quarterly conference call will be held on Thursday, August 1, 2019,
at 11:00 AM Eastern Time (ET) to review second quarter 2019
results. Ted Harris, Chairman of the Board, CEO and President and
Martin Bengtsson, CFO will host the call. We invite you to
listen to the conference by calling toll-free 1-877-407-8289 (local
dial-in 1-201-689-8341), five minutes prior to the scheduled start
time of the conference call. The conference call will be
available for replay two hours after the conclusion of the call
through end of day Thursday, August 15, 2019. To access the
replay of the conference call, dial 1-877-660-6853 (local dial-in
1-201-612-7415), and use conference ID #13692854.
Segment InformationBalchem
Corporation reports four business segments: Human Nutrition &
Health; Animal Nutrition & Health; Specialty Products; and
Industrial Products. The Human Nutrition & Health segment
delivers customized food and beverage ingredient systems, as well
as key nutrients into a variety of applications across the food,
supplement and pharmaceutical industries. The Animal Nutrition
& Health segment manufactures and supplies products to numerous
animal health markets. Through Specialty Products, Balchem provides
specialty-packaged chemicals for use in healthcare and other
industries, and also provides chelated minerals to the
micronutrient agricultural market. The Industrial Products segment
manufactures and supplies certain derivative products into
industrial applications.
Forward-Looking StatementsThis release contains
forward-looking statements, which reflect Balchem’s expectation or
belief concerning future events that involve risks and
uncertainties. Balchem can give no assurance that the expectations
reflected in forward-looking statements will prove correct and
various factors could cause results to differ materially from
Balchem’s expectations, including risks and factors identified in
Balchem’s annual report on Form 10-K for the year ended December
31, 2018. Forward-looking statements are qualified in their
entirety by the above cautionary statement. Balchem assumes no duty
to update its outlook or other forward-looking statements as of any
future date.
Contact: Mary Ann Brush, Balchem Corporation (Telephone:
845-326-5600)
Selected Financial Data (unaudited)($
in 000’s)
Business Segment Net Sales:
|
|
Three Months EndedJune 30, |
|
Six Months EndedJune 30, |
|
|
2019 |
|
2018 |
|
2019 |
|
2018 |
Human Nutrition & Health |
|
$ |
85,872 |
|
|
$ |
85,013 |
|
|
$ |
171,021 |
|
|
$ |
168,076 |
|
Animal Nutrition &
Health |
|
43,480 |
|
|
42,036 |
|
|
86,841 |
|
|
88,177 |
|
Specialty Products |
|
24,907 |
|
|
22,864 |
|
|
43,331 |
|
|
40,604 |
|
Industrial Products |
|
7,295 |
|
|
13,774 |
|
|
17,390 |
|
|
28,240 |
|
Total |
|
$ |
161,554 |
|
|
$ |
163,687 |
|
|
$ |
318,583 |
|
|
$ |
325,097 |
|
Business Segment Earnings Before Income
Taxes:
|
|
Three Months EndedJune 30, |
|
Six Months EndedJune 30, |
|
|
2019 |
|
2018 |
|
2019 |
|
2018 |
Human Nutrition & Health |
|
$ |
12,338 |
|
|
$ |
9,685 |
|
|
$ |
26,041 |
|
|
$ |
22,617 |
|
Animal Nutrition &
Health |
|
5,045 |
|
|
7,023 |
|
|
10,301 |
|
|
14,507 |
|
Specialty Products |
|
8,879 |
|
|
8,675 |
|
|
15,576 |
|
|
13,709 |
|
Industrial Products |
|
911 |
|
|
2,613 |
|
|
2,548 |
|
|
5,092 |
|
Transaction costs, integration
costs, and unallocated legal fees |
|
(761 |
) |
|
(893 |
) |
|
(1,565 |
) |
|
(1,582 |
) |
Unallocated amortization
expense |
|
(10 |
) |
|
— |
|
|
(19 |
) |
|
— |
|
Interest and other
expense |
|
(1,521 |
) |
|
(2,042 |
) |
|
(3,208 |
) |
|
(4,105 |
) |
Total |
|
$ |
24,881 |
|
|
$ |
25,061 |
|
|
$ |
49,674 |
|
|
$ |
50,238 |
|
Selected Balance Sheet
Items |
|
June 30, |
|
December 31, |
|
|
2019 |
|
2018 |
Cash and Cash Equivalents |
|
$ |
41,674 |
|
|
$ |
54,268 |
|
Accounts Receivable, net |
|
101,595 |
|
|
99,545 |
|
Inventories |
|
68,430 |
|
|
67,187 |
|
Other Current Assets |
|
20,186 |
|
|
5,314 |
|
Total Current Assets |
|
231,885 |
|
|
226,314 |
|
|
|
|
|
|
Property, Plant &
Equipment, net |
|
204,019 |
|
|
194,339 |
|
Goodwill |
|
506,852 |
|
|
447,995 |
|
Intangible Assets with Finite
Lives, net |
|
139,769 |
|
|
105,985 |
|
Right of Use Assets |
|
7,203 |
|
|
— |
|
Other Assets |
|
8,592 |
|
|
6,722 |
|
Total Assets |
|
$ |
1,098,320 |
|
|
$ |
981,355 |
|
|
|
|
|
|
Current Liabilities |
|
$ |
62,091 |
|
|
$ |
82,056 |
|
Revolving Loan |
|
228,569 |
|
|
156,000 |
|
Deferred Income Taxes |
|
57,386 |
|
|
44,309 |
|
Derivative Liabilities |
|
4,617 |
|
|
— |
|
Long-Term Obligations |
|
13,312 |
|
|
7,372 |
|
Total Liabilities |
|
365,975 |
|
|
289,737 |
|
|
|
|
|
|
Stockholders' Equity |
|
732,345 |
|
|
691,618 |
|
|
|
|
|
|
Total Liabilities and
Stockholders' Equity |
|
$ |
1,098,320 |
|
|
$ |
981,355 |
|
Balchem
CorporationCondensed Consolidated Statements of
Cash Flows(Dollars in thousands)(unaudited)
|
|
Six Months Ended June 30, |
|
|
2019 |
|
2018 |
Cash flows from
operating activities: |
|
|
|
|
Net earnings |
|
$ |
38,612 |
|
|
$ |
39,025 |
|
Adjustments to reconcile net earnings to net cash provided by
operating activities: |
|
|
|
|
Depreciation and
amortization |
|
21,732 |
|
|
22,426 |
|
Stock compensation
expense |
|
3,622 |
|
|
3,459 |
|
Other adjustments |
|
(2,187 |
) |
|
62 |
|
Changes in assets and
liabilities |
|
(12,967 |
) |
|
(18,276 |
) |
Net cash
provided by operating activities |
|
48,812 |
|
|
46,696 |
|
|
|
|
|
|
Cash flows from
investing activities: |
|
|
|
|
Cash paid for
acquisition, net of cash acquired |
|
(94,690 |
) |
|
— |
|
Capital expenditures
and intangible assets acquired |
|
(14,714 |
) |
|
(7,996 |
) |
Proceeds from insurance
and sale of assets |
|
2,729 |
|
|
2,166 |
|
Purchase of convertible
note |
|
(1,000 |
) |
|
— |
|
Net cash used
in investing activities |
|
(107,675 |
) |
|
(5,830 |
) |
|
|
|
|
|
Cash flows from
financing activities: |
|
|
|
|
Proceeds from revolving
debt |
|
108,569 |
|
|
210,750 |
|
Principal payments on
long-term and revolving debt |
|
(36,000 |
) |
|
(219,500 |
) |
Principal payments on
acquired debt |
|
(12,222 |
) |
|
— |
|
Proceeds from stock
options exercised |
|
1,809 |
|
|
6,578 |
|
Dividends paid |
|
(15,135 |
) |
|
(13,428 |
) |
Other |
|
(727 |
) |
|
(2,346 |
) |
Net cash
provided by (used in) financing activities |
|
46,294 |
|
|
(17,946 |
) |
|
|
|
|
|
Effect of exchange rate
changes on cash |
|
(25 |
) |
|
(860 |
) |
|
|
|
|
|
(Decrease) increase in
cash and cash equivalents |
|
(12,594 |
) |
|
22,060 |
|
|
|
|
|
|
Cash and cash
equivalents, beginning of period |
|
54,268 |
|
|
40,416 |
|
Cash and cash
equivalents, end of period |
|
$ |
41,674 |
|
|
$ |
62,476 |
|
Non-GAAP Financial Information
In addition to disclosing financial results in
accordance with United States (U.S.) generally accepted accounting
principles (GAAP), this earnings release contains non-GAAP
financial measures that we believe are helpful in understanding and
comparing our past financial performance and our future results.
The non-GAAP financial measures disclosed by the company exclude
certain business combination accounting adjustments and certain
other items related to acquisitions, certain unallocated equity
compensation, and certain one-time or unusual transactions. These
non-GAAP financial measures should not be considered a substitute
for, or superior to, financial measures calculated in accordance
with GAAP, and the financial results calculated in accordance with
GAAP and reconciliations from these results should be carefully
evaluated. Management believes that these non-GAAP measures provide
useful information about the Company's core operating results and
thus are appropriate to enhance the overall understanding of the
Company's past financial performance and its prospects for the
future. The non-GAAP financial measures in this press release
include adjusted gross margin, adjusted earnings from operations,
adjusted net earnings and the related adjusted per diluted share
amounts, EBITDA, adjusted EBITDA, adjusted income tax expense, and
free cash flow. EBITDA is defined as earnings before interest,
other expense/income, taxes, depreciation and amortization.
Adjusted EBITDA is defined as earnings before interest, other
expense/income, taxes, depreciation, amortization, stock-based
compensation, transaction and integration costs, indemnification
settlements, legal settlements, ERP implementation costs,
unallocated legal fees and the fair valuation of acquired
inventory. Adjusted income tax expense is defined as income
tax expense adjusted for the impact of ASU 2016-09. Free cash
flow is defined as net cash provided by operating activities less
capital expenditures.
Set forth below are reconciliations of the
non-GAAP financial measures to the most directly comparable GAAP
financial measures.
Table 1
Reconciliation of Non-GAAP Measures to
GAAP(Dollars in thousands, except per share
data)(unaudited)
|
|
Three Months Ended June 30, |
|
Six Months EndedJune 30, |
|
|
2019 |
|
2018 |
|
2019 |
|
2018 |
Reconciliation of
adjusted gross margin |
|
|
|
|
|
|
|
|
GAAP gross margin |
|
$ |
53,918 |
|
|
$ |
53,466 |
|
|
$ |
103,013 |
|
|
$ |
104,925 |
|
Amortization of intangible
assets (1) |
|
661 |
|
|
755 |
|
|
1,395 |
|
|
1,597 |
|
Adjusted gross margin |
|
$ |
54,579 |
|
|
$ |
54,221 |
|
|
$ |
104,408 |
|
|
$ |
106,522 |
|
|
|
|
|
|
|
|
|
|
Reconciliation of
adjusted earnings from operations |
|
|
|
|
|
|
|
|
GAAP earnings from
operations |
|
$ |
26,402 |
|
|
$ |
27,103 |
|
|
$ |
52,882 |
|
|
$ |
54,343 |
|
Amortization of intangible
assets (1) |
|
6,128 |
|
|
6,190 |
|
|
11,970 |
|
|
12,472 |
|
Transaction and integration
costs, ERP implementation costs, and unallocated legal fees
(2) |
|
761 |
|
|
893 |
|
|
1,565 |
|
|
1,582 |
|
Adjusted earnings from
operations |
|
$ |
33,291 |
|
|
$ |
34,186 |
|
|
$ |
66,417 |
|
|
$ |
68,397 |
|
|
|
|
|
|
|
|
|
|
Reconciliation of
adjusted net earnings |
|
|
|
|
|
|
|
|
GAAP net earnings |
|
$ |
19,829 |
|
|
$ |
19,679 |
|
|
$ |
38,612 |
|
|
$ |
39,025 |
|
Amortization of intangible
assets (1) |
|
6,199 |
|
|
6,621 |
|
|
12,112 |
|
|
13,012 |
|
Transaction and integration
costs, ERP implementation costs, and unallocated legal fees
(2) |
|
761 |
|
|
893 |
|
|
1,565 |
|
|
1,582 |
|
Income tax adjustment (3) |
|
(1,543 |
) |
|
(2,663 |
) |
|
(3,313 |
) |
|
(4,671 |
) |
Adjusted net earnings |
|
$ |
25,246 |
|
|
$ |
24,530 |
|
|
$ |
48,976 |
|
|
$ |
48,948 |
|
|
|
|
|
|
|
|
|
|
Adjusted net earnings per
common share - diluted |
|
$ |
0.77 |
|
|
$ |
0.76 |
|
|
$ |
1.51 |
|
|
$ |
1.51 |
|
(1) Amortization of intangible assets: Amortization of
intangible assets consists of amortization of customer
relationships, trademarks and trade names, developed technology,
regulatory registration costs, patents and trade secrets, and other
intangibles acquired primarily in connection with business
combinations. We record expense relating to the amortization of
these intangibles in our GAAP financial statements. Amortization
expenses for our intangible assets are inconsistent in amount and
are significantly impacted by the timing and valuation of an
acquisition. Consequently, our non-GAAP adjustments exclude these
expenses to facilitate an evaluation of our current operating
performance and comparisons to our past operating
performance.
(2) Transaction and integration costs, ERP implementation
costs and unallocated legal fees: Transaction and integration costs
related to acquisitions and divestitures are expensed in our GAAP
financial statements. ERP implementation costs related to a
company-wide ERP system implementation are expensed in our GAAP
financial statements. Unallocated legal fees for
transaction-related non-compete agreement disputes are expensed in
our GAAP financial statements. Management excludes these items for
the purposes of calculating Adjusted EBITDA and other non-GAAP
financial measures. We believe that excluding these items from our
non-GAAP financial measures is useful to investors because these
are items associated with each transaction and are inconsistent in
amount and frequency causing comparison of current and historical
financial results to be difficult.
(3) Income tax adjustment: For purposes of calculating
adjusted net earnings and adjusted diluted earnings per share, we
adjust the provision for (benefit from) income taxes to tax effect
the taxable and deductible non-GAAP adjustments described above as
they have a significant impact on our income tax (benefit)
provision. Additionally, the income tax adjustment is adjusted for
the impact of adopting ASU 2016-09, “Improvements to Employee
Share-Based Payment Accounting” and uses our non-GAAP effective
rate applied to both our GAAP earnings before income tax expense
and non-GAAP adjustments described above. See Table 3 for the
calculation of our non-GAAP effective tax rate.
The following table sets forth a reconciliation of Net Income
calculated using amounts determined in accordance with GAAP to
EBITDA and to Adjusted EBITDA for the three and six months ended
June 30, 2019 and 2018.
Table 2(unaudited)
|
|
Three Months Ended June 30, |
|
Six Months EndedJune 30, |
|
2019 |
|
2018 |
|
2019 |
|
2018 |
Net income - as reported |
|
$ |
19,829 |
|
|
$ |
19,679 |
|
|
$ |
38,612 |
|
|
$ |
39,025 |
|
Add back: |
|
|
|
|
|
|
|
|
Provision for income
taxes |
|
5,052 |
|
|
5,382 |
|
|
11,062 |
|
|
11,213 |
|
Other expense |
|
1,521 |
|
|
2,042 |
|
|
3,208 |
|
|
4,105 |
|
Depreciation and
amortization |
|
10,825 |
|
|
10,868 |
|
|
21,590 |
|
|
21,886 |
|
EBITDA |
|
37,227 |
|
|
37,971 |
|
|
74,472 |
|
|
76,229 |
|
Add back certain items: |
|
|
|
|
|
|
|
|
Non-cash compensation expense
related to equity awards |
|
1,991 |
|
|
1,666 |
|
|
3,622 |
|
|
3,459 |
|
Transaction and integration
costs, ERP implementation costs, and unallocated legal fees |
|
761 |
|
|
893 |
|
|
1,565 |
|
|
1,582 |
|
Adjusted EBITDA |
|
$ |
39,979 |
|
|
$ |
40,530 |
|
|
$ |
79,659 |
|
|
$ |
81,270 |
|
The following table sets forth a reconciliation of our GAAP
effective income tax rate to our non-GAAP effective income tax rate
for the six months ended June 30, 2019 and 2018.
Table 3(unaudited)
|
|
Six Months Ended June 30, |
|
2019 |
|
Effective Tax Rate |
|
2018 |
|
Effective Tax Rate |
GAAP Income Tax Expense |
|
$ |
11,062 |
|
|
22.3 |
% |
|
$ |
11,213 |
|
|
22.3 |
% |
Impact of ASU 2016-09
adoption(4) |
|
209 |
|
|
|
|
1,095 |
|
|
|
Adjusted Income Tax
Expense |
|
$ |
11,271 |
|
|
22.7 |
% |
|
$ |
12,308 |
|
|
24.5 |
% |
(4) Impact of ASU 2016-09 adoption: In March 2016, the FASB
issued ASU No. 2016-09, “Improvements to Employee Share-Based
Payment Accounting” (“ASU 2016-09”), which addresses the accounting
for share-based payment transactions, including the income tax
consequences, classification of awards as either equity or
liabilities, and classification on the statement of cash flows. The
Company adopted ASU 2016-09 on January 1,
2017 prospectively (prior periods have not been
restated). The primary impact of adoption was the recognition
during the three and six months ended June 30, 2019 and
2018, of excess tax benefits as a reduction to the provision
for income taxes and the classification of these excess tax
benefits in operating activities in the consolidated statement of
cash flows instead of financing activities. The presentation
requirements for cash flows related to employee taxes paid for
withheld shares had no impact to any of the periods presented in
the consolidated statement of cash flows, since such cash flows
have historically been presented in financing activities. The
Company also elected to continue estimating forfeitures when
determining the amount of stock-based compensation costs to be
recognized in each period. No other provisions of ASU 2016-09 had a
material impact on the Company’s financial statements or
disclosures.
The following table sets forth a reconciliation of net cash
provided by operating activities to free cash flow for the three
and six months ended June 30, 2019 and 2018.
Table 4(unaudited)
|
|
Three Months Ended June 30, |
|
Six Months EndedJune 30, |
|
|
2019 |
|
2018 |
|
2019 |
|
2018 |
Net cash provided by operating activities |
|
$ |
26,329 |
|
|
$ |
21,217 |
|
|
$ |
48,812 |
|
|
$ |
46,696 |
|
Capital expenditures |
|
(6,200 |
) |
|
(3,965 |
) |
|
(14,688 |
) |
|
(7,700 |
) |
Free cash flow |
|
$ |
20,129 |
|
|
$ |
17,252 |
|
|
$ |
34,124 |
|
|
$ |
38,996 |
|
Balchem (NASDAQ:BCPC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Balchem (NASDAQ:BCPC)
Historical Stock Chart
From Apr 2023 to Apr 2024